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the intravascular volume in the hyper-
tension-prone group. Th ese fi ndings sug-
gested the possibility that hypertension 
was driven by increased cardiac output. 
However, this was considered unlikely, 
because indirect determination of the 
cardiac output suggested that it decreased 
comparably in both groups and that sys-
temic vascular resistance increased in the 
hypertension-prone group.
Activation of the renin–angiotensin II 
system and activation of the sympathetic 
nervous system have been suggested as 
underlying defects for this syndrome, 
and renin, norepinephrine, and epine-
phrine were measured before and at the 
conclusion of dialysis. Th e control group 
showed the expected pattern with hemo-
dialysis and removal of more than 2 lit-
ers of fl uid: renin, norepinephrine, and 
epinephrine all rose signifi cantly.11 Inter-
estingly, these hormones did not increase 
in the hypertension-prone patients. Fur-
ther, an analysis of heart rate variability 
showed in controls, but not hypertension-
prone patients, a signifi cant elevation of 
the power index during the course of 
treatment that is indicative of increased 
sympathetic-to-parasympathetic activ-
ity. Neither increased hematocrit nor 
hypokalemia could explain the increase 
in resistance, and the authors suggest 
endothelial dysfunction with a nitric 
oxide–endothelin imbalance as a focus for 
future investigation. Vasopressin would 
also be a reasonable target for investiga-
tion, but, for now, the pathophysiology 
underlying increased resistance during 
hemodialysis with hypertension-prone 
patients remains a mystery.
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Detection of pattern of 
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of uremic cardiomyopathy 
necessary for management of 
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Cardiac magnetic resonance imaging (CMR) can detect cardiac tissue 
components for several kinds of cardiac myopathies. Mark et al. found 
two patterns of late gadolinium enhancement (LGE) in patients with 
uremic cardiomyopathy: focal LGE and diffuse LGE. The impact of 
these contrast-enhanced CMR findings on clinical outcomes warrants 
assessment in future studies.
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Cardiovascular disease is the main cause 
of death in patients with end-stage renal 
failure and accounts for almost 40% of 
the deaths in this population.1 However, 
uremic cardiomyopathy has not been 
investigated in detail, and its etiology and 
pathophysiology are unclear. One study 
showed that the pathologic characteris-
tics of uremic cardiomyopathy are severe 
myocyte hypertrophy, occasionally with 
disarray, and a high percentage area of 
fi brosis, and the extent of left  ventricular 
fi brosis was a strong predictor of cardiac 
death.2 Th e causes of these pathologic 
changes may be associated with vol-
ume overload, pressure overload, mal-
nutrition, anemia, uremic toxins, high 
catecholamine levels, and hyperparathy-
roidism. Hypertrophy due to pressure 
and volume overload is associated with a 
distinct myocyte phenotype and diff eren-
tial induction of peptide growth factors, 
which may stimulate both the loss and 
the hypertrophic growth of myocytes. 
Collagen fibers and other interstitial 
matrix molecules increase during hyper-
trophy, followed by the loss of myocytes 
due to myocardial injury.
From a clinical point of view, it is 
important to assess the cardiac function 
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and the underlying myocardial tissue 
composition of uremic cardiomyopathy. 
Several diagnostic tools are tested and 
used in daily practice. Echocardiography 
is the most common diagnostic tool used 
to evaluate the morphologic and func-
tional features of uremic cardiomyopathy. 
Uremic cardiomyopathy is echocardio-
graphically defined as left ventricular 
hypertrophy, dilatation dysfunction, 
and systolic dysfunction. However, it is 
especially diffi  cult to estimate diastolic 
dysfunction caused by myocardial fi bro-
sis. Although Doppler echocardiography 
and tissue Doppler imaging can detect 
diastolic dysfunction, echocardiographic 
diastolic markers such as E/A ratio (early 
diastolic peak velocity/late atrial diastolic 
peak velocity), deceleration time accord-
ing to left  ventricular infl ow, and Em/Am 
ratio (early diastolic myocardial tissue 
velocity/diastolic myocardial tissue veloc-
ity aft er atrial contraction) change fre-
quently in patients with end-stage renal 
failure. Th ese factors are easily infl uenced 
by the parameters of dialysis. In addi-
tion, echocardiography is not currently 
able to evaluate myocardial tissue com-
position. Multislice coronary computed 
tomography can detect coronary artery 
disease. Th e sensitivity and specifi city of 
a 64-slice computed tomography scanner 
for detecting signifi cant coronary artery 
stenosis are 99% and 95%, respectively.3 
Multislice computed tomography has 
the potential to complement diagnostic 
invasive coronary angiography in rou-
tine clinical care. However, this diagnos-
tic tool cannot detect the cardiac tissue 
components. Endomyocardial biopsy is 
currently the only diagnostic modality for 
detection of cardiac tissue composition. It 
can only diagnose the subendocardial tis-
sue, and biopsy is highly invasive. Th ere 
exists no ‘gold standard’ to evaluate ure-
mic cardiomyopathy.
Recently, cardiac magnetic resonance 
imaging (CMR) has been shown to be a 
promising technique that can accurately 
defi ne the dimensions and function of 
the left  ventricle. Furthermore, contrast-
enhanced CMR can detect cardiac tissue 
components for several kinds of cardiac 
myopathies, such as cardiac sarcoidosis, 
cardiac amyloidosis, and hypertrophic 
cardiomyopathy.4–6 In this issue, Mark 
et al. make signifi cant contributions by 
presenting a study of contrast-enhanced 
CMR for diagnosis of uremic cardiomy-
opathy.7 Th e authors found two patterns 
of late gadolinium enhancement (LGE) 
in patients with end-stage renal failure. 
Th e fi rst pattern is focal LGE involving 
the subendocardium, which represents 
myocardial infarction, and the second 
pattern is diffuse LGE, which most 
likely represents regional areas of dif-
fuse myocardial fi brosis. Focal LGE is 
associated with ischemic heart disease. 
Furthermore, CMR can be used to assess 
myocardial viability prior to revasculari-
zation.8 Th e indication for invasive coro-
nary angiography is easily decided aft er 
CMR. Currently, the problem is the clini-
cal results aft er coronary revasculariza-
tion. Renal dysfunction is a well-known 
risk factor for adverse cardiac events aft er 
coronary revascularization. Even mild 
renal dysfunction is associated with both 
restenosis and mortality aft er percuta-
neous coronary intervention. Coronary 
artery bypass graft ing is also associated 
with adverse outcome in patients with 
renal dysfunction. Renal dysfunction 
is an important factor in the calcula-
tion of risk scores for coronary artery 
bypass graft ing, according to American 
College of Cardiology/American Heart 
Association guidelines, the Cleveland 
Clinic score, and the European System 
for Cardiac Operative Risk Evaluation 
(EuroSCORE).  Th e two-year survival of 
dialysis patients aft er coronary revascu-
larization is very low (56.4% for coronary 
artery bypass graft ing and 48.4% for cor-
onary stenting), and the question of the 
best revascularization therapy is still con-
troversial.9  Recently, drug-eluting stents 
were defi nitively shown to dramatically 
reduce restenosis rates, even in patients 
with renal dysfunction.10 Less invasive 
and less frequent repeat revasculariza-
tion in these patients is likely to improve 
the clinical outcome.
The second pattern is diffuse LGE. 
Patients with diff use LGE had greater 
left ventricular hypertrophy and no 
impairment of left ventricular systo-
lic function.7 In addition, Mark et al. 
propose that this pattern is a feature of 
uremic cardiomyopathy itself and diff ers 
from myocardial hypertension or hyper-
trophic cardiomyopathy. In spite of the 
fact that the clinical impact of this pat-
tern is unknown, they suggest that this 
pattern may be associated with patients 
at high risk of arrhythmic sudden death, 
who have previously been diffi  cult to 
identify. Contrast-enhanced CMR may 
be an attractive noninvasive method to 
categorize these patients. Evaluation of 
arrhythmia is necessary for patients with 
diff use LGE.
Is it necessary to change the manage-
ment and treatment of patients with end-
stage renal failure, according to the three 
contrast-enhanced CMR patterns — no 
enhancement, focal enhancement, and 
diffuse enhancement? To answer this 
question, longer clinical follow-up and 
assessment of the impact of contrast-
enhanced CMR fi ndings on clinical out-
comes are warranted in future studies.
REFERENCES
1. Tyralla K, Amann K. Morphology of the heart and 
arteries in renal failure. Kidney Int Suppl 2003; 84: 
S80–S83.
2. Aoki J, Ikari Y, Nakajima H et al. Clinical 
and pathologic characteristics of dilated 
cardiomyopathy in hemodialysis patients. Kidney 
Int 2005; 67: 333–340.
3. Mollet NR, Cademartiri F, van Mieghem CA et al. 
High-resolution spiral computed tomography 
coronary angiography in patients referred for 
diagnostic conventional coronary angiography. 
Circulation 2005; 112: 2318–2323.
4. Smedema JP, Snoep G, van Kroonenburgh MP 
et al. Evaluation of the accuracy of gadolinium-
enhanced cardiovascular magnetic resonance 
in the diagnosis of cardiac sarcoidosis. J Am Coll 
Cardiol 2005; 45: 1683–1690.
5. Maceira AM, Joshi J, Prasad SK et al. 
Cardiovascular magnetic resonance in cardiac 
amyloidosis. Circulation 2005; 111: 186–193.
6. Moon JC, Reed E, Sheppard MN et al. The 
histologic basis of late gadolinium enhancement 
cardiovascular magnetic resonance in 
hypertrophic cardiomyopathy. J Am Coll Cardiol 
2004; 43: 2260–2264.
7. Mark PB, Johnston N, Groenning BA et al. 
Redefinition of uremic cardiomyopathy by 
contrast-enhanced cardiac magnetic resonance 
imaging. Kidney Int 2006; 69: 1839–1845. 
8. Kim RJ, Wu E, Rafael A et al. The use of contrast-
enhanced magnetic resonance imaging to 
identify reversible myocardial dysfunction. 
N Engl J Med 2000; 343: 1445–1453.
9. Herzog CA, Ma JZ, Collins AJ. Comparative 
survival of dialysis patients in the United States 
after coronary angioplasty, coronary artery 
stenting, and coronary artery bypass surgery 
and impact of diabetes. Circulation 2002; 106: 
2207–2211.
10. Halkin A, Mehran R, Casey CW et al. Impact of 
moderate renal insufficiency on restenosis and 
adverse clinical events after paclitaxel-eluting 
and bare metal stent implantation: results from 
the TAXUS-IV Trial. Am Heart J 2005; 150: 1163–
1170.
